|Last Price||Today's Change||52-Week Range||Trading Volume|
|104.82||0.32 (+0.31%)||82.51 - 154.89||919.5 thousand|
Market data as of 4:00PM 07/25/14. Quotes are delayed by at least 15 min.
IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study
05/31/2014 8:05 AM ET